Market Snapshot:
Neuralgia Patches topical anesthetic medication, causing impermanent deadness or loss of sensation in the area of application. , these patches are stretchy glue fix containing 5% lidocaine for the skin treatment of torment related to Post Herpetic Neuralgia (PHN). The first FDA-affirmed transdermal lidocaine fix was Lidoderm, in 1999, by Endo Pharmaceuticals Inc. Increasing the rate of back and neck pain is the key factor driving the development of the market. Nonetheless, the accessibility of choices for torment the board, for example, other agony executioner drugs is relied upon to control the development of the lidocaine patches market development.
Highlights from Neuralgia Patches Market Study
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
CAGR | 7.2% |
The key Players profiled in the report are Daiichi Sankyo (Japan), Acorda Therapeutics (United States), Purdue Pharma L.P (United States), Teikoku Pharma USA, Inc.(United States), Pfizer (United States), Teva Pharmaceutical Industries Ltd (Isreal), Mylan N.V. (United States) and Endo (Ireland). Additionally, other players that are part of this comprehensive study are Janssen Pharmaceuticals, Inc. (Belgium).
Geographic Breakdown and Segment Analysis
The Global Neuralgia Patches market presents a comprehensive analysis of the Neuralgia Patches market by product type (Capsaicin Skin Patches and Lidocaine Skin Patches), by end-user/application (Back Pain, Neck Pain, Shoulder Pain, Knees & Elbow Pain and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Neuralgia Patches industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
For instance, while the holds majority of market share of the Neuralgia Patches market
Analyst at AMA have segmented the market study of Global Neuralgia Patches market by Type, Application and Region.
Influencing Trend:
Advancements in Treatment Techniques for Neuralgia
Market Growth Drivers:
An increasing incidence of shingles is expected, Increase in the Prevalence of Postherpetic Neuralgia and Rising Geriatrics Population Across the World
Challenges:
Key competition between manufacturers
Restraints:
The availability of alternatives for pain management such as other pain killer drugs.
Opportunities:
The growing number of a generic approved product and Development of Health Care Infrastructure in Developed as well as Developing Countries
Market Developments Activities:
In
In December 2020 The capsaicin dermal patch has been introduced in the US for the treatment of pain associated with postherpetic neuralgia. The product has also been debuted in Europe for the broad label of peripheral neuropathic pain, including postherpetic pain and HIV-associated neuropathies, in non-diabetic adults.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail a competitive advantage through combined collaborations.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Neuralgia Patches Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry